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Objective: To evaluate the impact of alcohol use, which is widespread in human 
immunodeﬁ  ciency virus (HIV)+ individuals, on highly active antiretroviral therapy (HAART)-
associated immune and cognitive improvements and the relationship between those two 
responses.
Methods: In a case-control longitudinal study, thymic volume, cognition, and immune responses 
were evaluated at baseline and after 6 months therapy in HIV+ and HIV- controls. Cognitive 
performance was evaluated using the HIV Dementia Score (HDS) and the California Verbal 
Learning Test (CVLT).
Results: Prior to HAART, thymic volume varied considerably from 2.7 to 29.3 cm3 
(11 ± 7.2 cm3). Thymic volume at baseline showed a signiﬁ  cantly inverse correlation with 
the patient’s number of years of drinking (r2 = 0.207; p  0.01), as well as HDS and the 
CVLT scores in both HIV-infected (r2 = 0.37, p = 0.03) and noninfected (r2 = 0.8, p = 0.01). 
HIV-infected individuals with a small thymic volume scored in the demented range, as 
compared with those with a larger thymus (7 ± 2.7 vs. 12 ± 2.3, p = 0.005). After HAART, 
light/moderate drinkers exhibited thymus size twice that of heavy drinkers (14.8 ± 10.4 vs. 
6.9 ± 3.3 cm3).
Conclusions: HAART-associated increases of thymus volume appear to be negatively affected 
by alcohol consumption and signiﬁ  cantly related to their cognitive status. This result could have 
important clinical implications.
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Introduction
The human immunodeﬁ  ciency virus (HIV) epidemic is a major international pub-
lic health problem (WHO 2005). Although the primary target of this virus is the 
immune system, neurological abnormalities are common in patients infected with 
HIV (Bean 2001). The immune system and central nervous system (CNS), once 
considered completely independent, have been demonstrated to be closely linked 
(Dalakas et al 1986; Fabris et al 1988; Spangelo 1995; Antoniou et al 1997; Turrini 
et al 1998; Savino and Dardenne 2000; Nishiyama 2001; Morale et al 2003; Cavalloti 
et al 2005; Fleming et al 2005). Bidirectional communication between the brain and 
the thymus has been described in numerous studies, in association with cytokines, 
hormones, growth factors, and neurotransmitters (Fabris et al 1988; Antoniou et al 
1997; Morale et al 2003; Cavalloti et al 2005). These factors enable the thymus, 
which plays a critical role during highly active antiretroviral therapy (HAART) 
reconstitution, to act at sites distant from it, and it inﬂ  uences the ontogenesis and 
function of both the immune system and CNS. Unfortunately, its role has been 
overlooked in terms of HIV disease. Therefore, the present study explored the role 
of alcohol use in cognitive impairment and recuperation from HAART through its 




Participants aged 18 to 55 years, who had been diagnosed with 
HIV and had been receiving a new antiretroviral regimen for 
less than 10 weeks, were eligible to be enrolled in the Miami 
Alcohol Research Care for HIV (MARCH) study. Brieﬂ  y, 
MARCH is a longitudinal observational study to evaluate 
the impact of alcohol use on health status of HIV-infected 
individuals receiving HAART. Participants were recruited 
from the University of Miami Miller School of Medicine 
and Jackson Memorial clinics, where these individuals are 
followed at regular intervals. Antiretroviral eligibility criteria 
were as follows: HIV-infected subjects could be either 1) naïve 
or 2) had prior exposure to antiretroviral therapy, but they 
must have discontinued HAART for at least 6 weeks prior to 
starting this new regimen. The HIV cohort was matched by 
stratifying gender, age, and race with an HIV seronegative (as 
per laboratory testing during the previous six months) com-
munity control, consisting of friends and relatives of enrolled 
participants for comparing study outcomes.
Participants were divided into hazardous (Group 1) and 
nonhazardous drinkers (Group 2), according to National Insti-
tute of Alcohol and Alcohol Abuse (NIAAA) and American 
Association guidelines (Fleming 2005). Alcohol consumption 
assessments included widely-used standardized and validated 
brief screening questionnaires: Physician’s Guide (NIAAA) 
(Fleming 2005), Cut, Annoyed, Guilty, Eye opener (CAGE), 
Alcohol Use Disorder Identiﬁ  cation Test (AUDIT), and 
Alcohol Dependence Scale (ADS). Men who reported 14 
and women 7 or more drinks/week were enrolled in Group 
1, while those who reported fewer drinks were included in 
Group 2. Those who provided written informed consent and 
medical release were enrolled. The Institutional Review Board 
at the University of Miami approved the study.
Using standardized questionnaires, the following data 
were collected: sociodemographic information, drugs, alcohol 
use habits, and past and current medical history. HIV positives 
were questioned with acquired immunodeﬁ  ciency syndrome 
(AIDS)-deﬁ  ning Centers for Disease Control and Prevention 
(CDC) criteria to establish HIV disease status. Medical pre-
scriptions were documented and a standardized antiretroviral 
adherence questionnaire administered. After visit procedures 
were completed, a medical chart and pharmacy records were 
abstracted and patient information was validated.
Immune assessments
Blood samples were collected from all participants and pro-
cessed within 6 hours. Isolated peripheral blood mononuclear 
cells were prepared for four-color direct immunoﬂ  uorecence 
procedures (Becton Dickinson, San Jose, CA). Flow cytom-
etry quantiﬁ  ed the percentage and absolute numbers of 
T lymphocyte sub populations CD3+/CD4+ and CD3+/CD8. 
In addition, HIV viral burden was quantiﬁ  ed using the Ampli-
cor HIV monitor test (Roche Diagnostic System).
Thymus
Magnetic resonance (MR) imaging was selected over 
computed tomography (CT) because MR provides superior 
soft tissue contrast, and avoids the use of ionizing radiation 
and contrast administration (De Geer et al 1986; Watzl 
et al 1993). The MR was obtained only in a sub-sample of 
patients that, were adherent to their prescribed medication 
after the ﬁ  rst month. The MR was performed using a thoracic 
surface coil and electrocardiographic gating, and consisted 
of the following sequences: 1) Sagittal and coronal pilots; 
2) T1-weighted axial, slice thickness 6 mm, interslice gap 
1 mm, 4 averages; and 3) T2-weighted axial fat-suppressed, 
slice thickness 6 mm, interslice gap 1 mm, 4 averages. 
Thymic volume can be estimated from the sum of the areas 
of manually drawn regions-of-interest from each image on 
which glandular thymic tissue appears. However, the adult 
thymus is generally fatty involuted, and calculations of true 
glandular volume may be inaccurate if fatty elements are not 
excluded. Therefore, we instead performed a quantitative 
thymic volume calculation by measuring total mediastinal 
area, mean mediastinal signal intensity (SI [mediastinum]), 
fat signal intensity (SI [fat]), and muscle signal intensity (SI 
[muscle]) on each T1 weighted slice. We assumed that pure 
glandular (thymic) tissue would have a signal intensity simi-
lar to that of muscle, whereas a completely fatty involuted 
thymus would have a signal intensity of fat. For each slice 
from the left brachiocephalic vein superiorly to the main 
pulmonary artery inferiorly, we then calculated thymic area 
using the following formula:
Quantitative thymic area




The sum of thymic areas was then multiplied by the slice 
thickness plus interslice gap (7 mm) to obtain total thymic 
volume.
Cognition
The HIV Dementia Scale (HDS) was used as a valid screen-
ing tool with 10 as a cutoff point. The HDS had a sensitivity 
of 80%, speciﬁ  city 91%, and positive predictive value 78% 
for identifying HIV dementia (Power et al 1995). The HDS Biologics: Targets & Therapy 2008:2(2) 323
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was shown as superior to other widely used rapid screen-
ing tests (Mini-Mental State Examination). In addition, it 
has been previously used to monitor therapeutic effects on 
the CNS (Dougherty et al 2002). The HDS is comprised of 
four tasks that evaluate the domains of memory, attention, 
psychomotor speed, and construction.
The California Verbal Learning Test (CVLT) is a multi-
dimensional measure of verbal learning and memory, which 
includes two word lists, each of which contains 16 shopping 
items (Delis et al 1987). Items are distributed according to a 
Monday list and a Tuesday distracter list, with scores repre-
senting the number of objects that an individual can recall. 
Participants are asked to recall the Monday list spontaneously, 
following semantic cues and after a 20-minute delay. Finally, 
participants are given a “yes/no” recognition test in which 
they are presented with the 16 target words embedded within 
a list of 28 nontarget words. Scores are based on the number 
of words provided by the participant on the various trials and 
on the number of times they correctly identify a word to be a 
member or not of the ﬁ  rst list (Delis et al 1987).
Statistical analyses
The data were analyzed using SAS version 8 (SAS Institute 
Inc., Cary, NC) and SPSS version 11 (SPSS Inc., Chicago, 
IL) and p values 0.05 were considered to be statistically 
signiﬁ  cant. Following descriptive statistical analyses, mean 
variables were compared using Student’s t-test and one-way 
analysis of variance (ANOVA) procedures. Correlations 
among the main variables of interest were examined with 
Pearson’s coefﬁ  cients.
Logistic regression analyses were used to evaluate the 
effects of alcohol, HAART, and other potential risk factors 
on cognition. Univariate analyses were used to calculate odds 
ratios (OR) and 95% conﬁ  dence intervals (CI).
To identify the pattern of change in cognitive status over 
time and under the effect of HAART (no change, decrease, or 
increase), differences in average scores between baseline and 
second visit evaluation were assessed using t-tests for paired 
samples and analyzed by thymus size and alcohol groups.
Finally, linear regression analyses were performed for 
each comparison. Although no signiﬁ  cant differences were 
observed between groups for education level or CDC status, 
both variables were controlled for in the ﬁ  nal analyses.
Results
Study population characteristics
This longitudinal study assessed a multiethnic sample of 
162 HIV-infected subjects, including 89 hazardous drinkers 
and 73 nonhazardous drinkers. The 35 HIV seronegative 
participants included 20 hazardous and 15 nonhazardous 
drinkers. Participants ranged in age from 24 to 54 years (mean 
40 ± 7 years). More than half (66%) of the participants were 
male and 34% were female. Years of education varied across 
the sample from 1–16 years (mean 11.4 ± 3 years) and 25% 
had more than 12 years of education.
Approximately one-third of the participants acknowl-
edged current drug abuse, particularly crack/cocaine and 
marijuana.
The sample reported an average of 20 ± 2 drinks/week, 
along with a well-documented history of continuous alcohol 
consumption averaging 8 ± 7 drinks per day for more than 
a month prior to sampling. Despite receiving HAART, the 
HIV-infected group reported average weekly alcohol con-
sumption similar to the seronegative individuals (22 ± 2.5 vs. 
25 ± 4.3 drinks). No signiﬁ  cant difference in any of the 
above mentioned characteristics was observed between HIV 
seropositives and seronegatives.
The mean CD4 cell count of the total group was 
255.3 ± 242.8. On average, the study sample had a viral 
load of 227,899 ± 140,834 copies. Only half of the study 
participants reported full adherence to their medication and 
received a MR evaluation (Table 1).
Cognition
At baseline, 60% of HIV positives had total scores below 
9 of 16 possible points, indicating dementia. No signiﬁ  cant 
correlations were found between the HDS scores and age, 
education, viral load, CD4, or drug use.
A signiﬁ  cant correlation was observed between total 
drinks per week and mental status, as indicated by baseline 
total HDS (r2 = 0.22, p = 0.003). The seronegative nonhazard-
ous drinkers exhibited the highest HDS scores (12.5 ± 3.8), 
followed by HIV-infected nonhazardous drinkers (10.4 ± 4), 
HIV seronegative hazardous drinkers (8.6 ± 5 total score), 
and those with dual co-morbidity (8.4 ± 3.7). No signiﬁ  cant 
Table 1 Baseline characteristics of study population by alcohol 
consumption
Characteristics Nonhazardous  Hazardous
 drinkers  drinkers
Number of individuals (%)  73 (45)  89 (55)
Number of women (%)  20 (27.4)  35 (39.3)
Mean (SD) age (years)  40.7 (7.3)  40.5 (7.5)
Education (SD) (years)  11.0 (0.07)  11.8 (0.10)
CD4 cell counts (SD)  253 (179)  256 (184)
Data are mean (SD) or numbers (%), unless otherwise indicated.Biologics: Targets & Therapy 2008:2(2) 324
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effects of gender, age, or education were observed in HDS 
total scores.
The correlation between alcohol drinks/week and HDS 
score remained significant after six months of HAART 
(r = 0.16, p = 0.02). Signiﬁ  cantly low mean HDS total 
scores were noted in hazardous alcohol users, compared with 
nonhazardous alcohol users (df = 162, F = 1.94; 9.2 ± 3.5 vs. 
10.5 ± 3.8, p = 0.04). Moreover, all HIV-infected heavy alco-
hol users scored 8 on the HDS. Univariate analyses indicate 
that HIV-infected hazardous alcohol users were more likely 
to have dementia compared with seronegative nondrinkers 
(OR = 1.7, 95% CI: 1–2.38, p = 0.05). After HAART, paired 
t-test analyses indicated no changes in total HDS scores in 
either hazardous alcohol users or nonhazardous drinkers.
Negative correlations were evident between drinks/week 
and both Monday (r2 = −0.21, p = 0.009) and Tuesday recalls 
(r2 = −0.15, p = 0.04). No signiﬁ  cant correlations were found 
between the CVLT and age, gender, level of education, or 
drug use. Low mean Monday scores on the CVLT were evi-
dent in the seronegative nonhazardous drinkers, as compared 
with the seronegative hazardous drinkers (df = 35, F = 1.18; 
11.4 ± 2.9 vs. 10 ± 3.7, p = 0.04), and were also lower for 
the Tuesday list (df = 35, 5 ± 2 vs. 7.6 ± 2.6, p = 0.003). The 
groups also tended to differ in the long delay free recall test 
(df = 35, 11.6 ± 3 vs 9.3 ± 4 words, p = 0.07). Low mean 
scores on the CVLT were evident in HIV-infected hazardous 
alcohol drinkers. Recall for both short and long delays was 
poorer in HIV-infected hazardous alcohol drinkers (df = 162, 
8 ± 3 and 9 ± 4 items, respectively) than in HIV-infected 
nonhazardous alcohol drinkers (df = 162, 9.5 ± 3.7 items, 
p = 0.05; 10 ± 4 words, p = 0.06; See Table 2.). Delay rec-
ognition scores were also signiﬁ  cantly worse in HIV-infected 
hazardous alcohol drinkers than in HIV nonhazardous 
drinkers (df = 162, F = 2.49; 10.5 ± 3.7 words vs. 12.8 ± 3.2 
words, p = 0.03).
Statistically signiﬁ  cant improvement in short memory 
tasks (change = 1–2 words) was evident after six months of 
HAART in both hazardous alcohol drinkers (p = 0.001) and 
nonhazardous alcohol drinkers (p = 0.001). The previous 
observed difference in the HIV positive groups persisted at 
the six-month evaluation. Hazardous alcohol drinkers were 
twice as likely as nonhazardous alcohol drinkers to forget 
more words (remember less than 10/15 words, 95% CI: 
1–6.6; p = 0.04). Long delay free recall remained signiﬁ  -
cantly lower after HAART treatment in hazardous alcohol 
drinkers, than in HIV-infected nonhazardous alcohol drinkers 
(df = 162, F = 1.94; 8.8 ± 3 words vs. 10.4 ± 4; p = 0.03). 
No signiﬁ  cant changes between baseline and six-month 
evaluations were evident in any of the study parameters in 
the noninfected group.
Baseline cognitive performance 
according to immune parameters
Thymus size was signiﬁ  cantly correlated with total HDS 
score (r2 = 0.5, p = 0.05) at baseline. Patients were separated 
into those with thymus volumes above or below 13 cm3, 
which corresponds to the mean volume of the HIV negative 
control population. Participants with a small thymus scored 
in the demented range (7 ± 2.7) compared with those with 
a larger thymus (df = 87, F = 2.6; 12 ± 2.3, p = 0.005). 
Importantly, a smaller thymus size was characteristic of 
HIV-infected hazardous alcohol drinkers and none and/or no 
signiﬁ  cant improvement in CD4 cell counts after 6 months 
of treatment (Figure 1).
Thymus size was also correlated with the CVLT scores 
in both HIV-infected (r2 = 0.37, p = 0.03) and noninfected 
Table 2 Cognitive and immune baseline characteristics
Characteristics Nonhazardous  Hazardous
 drinkers  drinkers
HIV dementia scores (HDS)  10.4 ± 4  8.4 ± 4
CVLT short delay recall  9.5 ± 4  8 ± 3
CVLT long delay recall  10 ± 4  9 ± 4
Viral load  177, 810 ± 36, 290  233, 778 ± 35, 674
CD4 cell counts (SD)  253 ± 179  256 ± 184
Notes: Data are mean (SD) or numbers (%), unless otherwise indicated.
Abbreviations: HDS, HIV dementia scale; CVLT, California Verbal Learning Test.
Figure 1 Axial T1 weighted image of the thymus of an antiretroviral treated 
nonhazardous drinker. The thymus (arrow) is of intermediate signal intensity with small 
amounts of higher intensity fat (arrowheads) around it.Biologics: Targets & Therapy 2008:2(2) 325
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participants (r2 = 0.8, p = 0.01). Correlations between CVLT 
scores and thymus size were generally highest among HIV-
infected individuals. A positive, signiﬁ  cant correlation was 
also noted between thymus size and the Monday recall 
list (r2 = 0.4, p = 0.05). Univariate analyses indicated that 
patients with a thymus size 13 cm3 were 5 times more 
likely to recall more than 8 words in the Monday list (95% 
CI: 1.2–16.0, p = 0.02).
HIV-infected participants with more than 200 CD4 cell 
counts exhibited similar total HDS (10.1 ± 3.9 vs. 9.4 ± 3.3) 
and CVLT (11.7 ± 3.3 vs. 10.9 ± 2.6; p  0.05) scores, as 
compared with those with less than 200 CD4 cell counts.
After 6 months of HAART
After 6 months of HAART, thymus volumes increased an 
average of 25% (5 ± 3 cm3). On average, nonhazardous 
alcohol drinkers signiﬁ  cantly improved their CD4 by 20 
cell counts (p = 0.04), which contrasted with only a 3 cell 
improvement among the hazardous alcohol drinkers. Accord-
ingly, those with a large thymus improved on average by 25 
cell counts, while those with a small thymus lost 34 CD4+ cell 
counts despite treatment. The sample sizes were insufﬁ  cient 
to allow analyses by regimen type or by CNS penetration.
After HAART, a slight increase in mean HDS scores was 
observed in all groups, except for the hazardous drinkers 
with a small thymus. Nonhazardous drinkers with a larger 
thymus after HAART exhibited the highest HDS scores 
(13.8 ± 1.3), followed by nonhazardous drinkers with a 
small thymus (11.6 ± 2.4), hazardous drinkers with a small 
thymus (8.9 ± 5 total score), and those with dual co-morbidity 
(7.4 ± 2.7). Longitudinal analyses indicated that participants 
with a smaller thymus were twice as likely to score in the 
demented range as those with a larger thymus (RR = 1.6, 
95% CI: 1–2.3, p = 0.05).
Statistically signiﬁ  cant improvement in short memory 
tasks (change = 1–2 words) was also evident in both hazard-
ous alcohol drinkers (p = 0.001) and nonhazardous alcohol 
drinkers (p = 0.001). The correlation between thymus size 
and short-delay recall was even stronger (r2 = 0.6, p = 0.008) 
after HAART. Thymus size also correlated with long delay 
free recall (r2 = 0.7, p = 0.003). Additional analyses indicated 
signiﬁ  cantly poorer recall scores in HIV seropositives with a 
smaller thymus (short delay: 8.9 ± 2.4 words and long delay: 
9.1 ± 2.6 words), compared with those with a normal size 
thymus (13.6 ± 2.8 items, p = 0.01; 13 ± 3.4 words, p = 0.05; 
See Table 3). After HAART, HIV-infected subjects with a 
small thymus were still twice as likely as HIV positives with 
13 cm of thymus to remember fewer than 8 items in the 
Monday list (95% CI: 1.1–4.4, p = 0.04). They were also 
less likely to remember more than 5 items in the Tuesday 
list (RR = 6, p = 0.03).
Patients that increased their thymus size after HAART 
had significantly improved recall (Monday list change 
2 ± 0.8, p = 0.03) and long delayed free recall (1.9 ± 0.6, 
p = 0.01). In contrast, no signiﬁ  cant improvement in recall 
was shown for those whose thymus failed to increase in size 
(Monday 0.2 ± 0.1 and long delayed 0.4 ± 0.1).
In the ﬁ  nal analyses, age, CDC stage, alcohol consump-
tion, education, and thymus size were included as dichoto-
mous variables in the ﬁ  nal regression model with HDS as 
the dependent variable. As illustrated in Table 4, hazardous 
alcohol consumption (RR = 9; 95% CI: 1.0–98, p = 0.04) and 
small thymus (RR = 7.5; 95% CI: 1.5–38, p = 0.01) were the 
only variables associated with HIV dementia after adjusting 
for potential confounders.
Figure 2 Axial T1 weighted image of the thymus of an antiretroviral treated haz-
ardous drinker.   The mediastinum largely consists of high intensity fat, with a small 
thymus (black arrow).
Table 3 Cognitive and immune measurements after 6 months of 
HAART according to thymus size
Characteristics Small  thymus  Large  thymus  p Value
HIV dementia scores   8.0 ± 4.7  11.7 ± 3  0.03
(HDS)
CVLT short delay recall  8.9 ± 2.4  13.6 ± 2.8  0.01
CVLT long delay recall  9.1 ± 2.6  13 ± 3.4  0.05
CD4 cell counts (SD)  −34 ± 7  25 ± 4  0.05
Data are mean (SD) or numbers (%), unless otherwise indicated.
Abbreviations: CVLT, California Verbal Learning Test; HAART, highly active antiret-
roviral therapy; HDS, HIV dementia scale; SD, standard deviation.Biologics: Targets & Therapy 2008:2(2) 326
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Discussion
Until recently, it was thought that a close interaction between 
the thymus and the CNS only occurred during development. 
However, we have made a remarkable medical discovery in 
humans. The thymus is closely related to cognitive status 
in HIV-infected and noninfected adults. Furthermore, 
additional analyses indicated that cognitive task restoration 
following HAART administration is associated with thymus 
regeneration and impacted by alcohol consumption.
Thymus size effects were evident at baseline in both HDS 
and CVLT tests and observed in both HIV-infected and non-
infected participants. Notably, correlations were generally 
highest among HIV-infected individuals and related to the 
deleterious effects of alcohol and HIV in these individuals. 
These ﬁ  ndings conﬁ  rm and extend previous animal studies 
that have found a signiﬁ  cant relationship between cognitive 
and CNS structural changes and thymus (Song and Bao 1991; 
Saito et al 1994; Zhang et al 1994; Wang and Spitzer 1997). 
Athymic mice and thymectomized rats have been reported 
to exhibit memory impairment in spatial and conditioned 
memory. Alterations in learning performance have been con-
sistently observed at 3, 5, and 10 months post-thymectomy, 
suggesting that the thymus signiﬁ  cantly inﬂ  uenced learning 
and memory ability (Song and Bao 1991; Saito et al 1994; 
Zhang et al 1994; Wang and Spitzer 1997; Nishiyama 2001). 
The operation also results in an underdeveloped brain with a 
thin cortex and changes in learning performance. However, 
if the thymus is re-implanted, the frontal area becomes as 
thick as normal (Song and Bao 1991; Saito et al 1994; Zhang 
et al 1994; Wang and Spitzer 1997). These ﬁ  ndings are of 
particular relevance to our study, as neuropsychological 
disturbances associated with HIV-1 infection are consistent 
with dysfunction of frontal-subcortical circuitry (Meyerhoff 
2001). Cytokines, prolactin, and thymosins are some of 
many candidates for the role of messengers mediating thy-
mus induction of cognitive and psychobehavioral disorders 
(Fabris et al 1988; Song and Bao 1991; Saito et al 1994; 
Zhang et al 1994; Spangelo 1995; Antoniou et al 1997; Wang 
and Spitzer 1997; Turrini et al 1998; Savino and Dardenne 
2000; Nishiyama 2001; Morale et al 2003; Cavalloti et al 
2005). These ﬁ  ndings conﬁ  rm that our results have solid 
physiopathological reasons and represent more than a for-
tuitous association.
In line with this notion, our data also indicate for the 
ﬁ  rst time that alcohol-induced impaired mental status in 
HIV positive subjects is, at least in part, mediated by its 
effects over the thymus. Findings indicated that thymus 
atrophy is more evident in hazardous alcohol users and that 
the deleterious effect on the thymus impacts learning and 
memory ability. This is in accord with publications in the 
1980s and early 1990s that alcohol use affects the size and 
weight of the thymus in animal models and in infants exposed 
to alcohol in utero (Song and Bao 1991; Saito et al 1994; 
Zhang et al 1994; Wang and Spitzer 1997). Potential mecha-
nisms mediating alcohol-induced thymic alterations include 
apoptotic changes, impaired mitochondrial function, and 
decreased total glutathione and antioxidant concentrations 
in thymocytes (Song and Bao 1991; Saito et al 1994; Zhang 
et al 1994; Wang and Spitzer 1997). Possible interactive 
effects of ethanol and HIV infection in the CNS have been 
explored through studies of oxidative stress and interleukins. 
Findings from these studies reveal that both alcohol and 
HIV may increase oxidative stress in the brain and produce 
pro-inﬂ  ammatory and TH2 interleukins (Meyerhoff 2001). 
These results are of relevance to our ﬁ  ndings, as the thymus 
regulates a number of the interleukins and thymic hormones, 
which have been demonstrated to reduce damage induced by 
oxidative stress in the CNS (Fabris et al 1988; Song and Bao 
1991; Saito et al 1994; Zhang et al 1994; Wang and Spitzer 
1997; Spangelo 1995; Antoniou et al 1997; Turrini et al 1998; 
Savino and Dardenne 2000; Nishiyama 2001; Morale et al 
2003; Cavalloti et al 2005).
Before HAART, patients with HIV-associated dementia 
(HAD) typically experienced rapid deterioration over a few 
months (Suarez et al 2001; McArthur et al 2005). HAART 
has played a major role in modifying the course of HAD 
(McArthur et al 2005). Encouragingly, our data, along with 
others, indicate some improvements in neuropsychologi-
cal test performance abnormalities after starting HAART, 
but progress is not observed in all participants who were 
Table 4 Odds ratios for dementia according to alcohol intake
Model  Univariate OR  95% CI  Multivariate OR  95% CI  Df  F  p Value
Regression        87  6.109  0.05
Drinker  1.23  1–4.1  9  1–98    0.04
Thymus 1.6  1–2.3  7.5  1.5–38     0.001
Abbreviations: OR, odds ratio; CI, Conﬁ  dence interval.Biologics: Targets & Therapy 2008:2(2) 327
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receiving and maintained adherence to HAART (McArthur 
et al 2005). The mechanism hindering HAART’s beneﬁ  cial 
responses in some subjects, but not in others, remains largely 
unclear (McArthur et al 2005). Of interest, improvements in 
cognitive tasks after 6 months of HAART in our study were 
not associated with viral loads, CD4 counts, or age, but rather 
with thymus restoration, which is undermined by alcohol 
consumption. These ﬁ  ndings further conﬁ  rm our hypothesis 
regarding the role of thymus in the CNS.
Although the HDS and the CVLT cannot solely determine 
the presence of dementia in HIV-infected subjects, study 
participants were limited to those followed at University of 
Miami facilities, and MR was obtained only in a sub-sample 
of participants, our ﬁ  ndings do illustrate the relationship 
between the thymus and neuropsychological functioning in 
both HIV disease and alcohol abuse, which was overlooked 
until now. These exciting results have improved understanding 
of the neuro-immune systems. The ﬁ  ndings reported here 
should be tested with a comprehensive cognitive battery and, 
if supported by further studies, may have important clinical 
and therapeutic implications for neuroimmune diseases, when 
considering that several pathways manipulate the thymus and 
thymus-related substances.
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